Show simple item record

dc.contributor.authorElamir, Amal
dc.contributor.authorAysha Ajith, Saniha
dc.contributor.authorAlSawaftah, Nour Majdi
dc.contributor.authorAbuwatfa, Waad Hussein
dc.contributor.authorMukhopadhyay, Debasmita
dc.contributor.authorPaul, Vinod
dc.contributor.authorAl-Sayah, Mohammad
dc.contributor.authorAwad, Nahid S.
dc.contributor.authorHusseini, Ghaleb
dc.date.accessioned2021-04-07T04:34:00Z
dc.date.available2021-04-07T04:34:00Z
dc.date.issued2021
dc.identifier.citationElamir, A., Ajith, S., Sawaftah, N. A., Abuwatfa, W., Mukhopadhyay, D., Paul, V., Al-Sayah, M. H., Awad, N., & Husseini, G. A. (2021). Ultrasound-triggered herceptin liposomes for breast cancer therapy. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-86860-5en_US
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11073/21389
dc.description.abstractThe functionalization of liposomes with monoclonal antibodies is a potential strategy to increase the specificity of liposomes and reduce the side-effects associated with chemotherapeutic agents. The active targeting of the Human Epidermal growth factor Receptor 2 (HER2), which is overexpressed in HER2 positive breast cancer cells, can be achieved by coating liposomes with an anti-HER2 monoclonal antibody. In this study, we synthesized calcein and Doxorubicin-loaded immunoliposomes functionalized with the monoclonal antibody Trastuzumab (TRA). Both liposomes were characterized for their size, phospholipid content and antibody conjugation. Exposing the liposomes to low-frequency ultrasound (LFUS) triggered drug release which increased with the increase in power density. Trastuzumab conjugation resulted in enhancing the sensitivity of the liposomes to LFUS. Compared to the control liposomes, TRA-liposomes showed higher cellular toxicity and higher drug uptake by the HER2 + cell line (SKBR3) which was further improved following sonication with LFUS. Combining immunoliposomes with LFUS is a promising technique in the field of targeted drug delivery that can enhance efficiency and reduce the cytotoxicity of antineoplastic drugs.en_US
dc.description.sponsorshipAmerican University of Sharjahen_US
dc.description.sponsorshipAl-Jalila Foundationen_US
dc.description.sponsorshipAl Qasimi Foundationen_US
dc.description.sponsorshipPatient’s Friends Committee-Sharjahen_US
dc.description.sponsorshipBiosciences and Bioengineering Research Instituteen_US
dc.description.sponsorshipGCC Co-Fund Programen_US
dc.description.sponsorshipTakamul programen_US
dc.description.sponsorshipTechnology Innovation Pioneer (TIP) Healthcare Awardsen_US
dc.description.sponsorshipDana Gas Endowed Chair for Chemical Engineeringen_US
dc.language.isoen_USen_US
dc.publisherNatureen_US
dc.relation.urihttps://doi.org/10.1038/s41598-021-86860-5en_US
dc.titleUltrasound‑triggered herceptin liposomes for breast cancer therapyen_US
dc.typePeer-Revieweden_US
dc.typeArticleen_US
dc.typePublished versionen_US
dc.identifier.doi10.1038/s41598-021-86860-5


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record